HeartBeam Consensus Price Target Increased by 10.53% to $3.57
The average one-year price target for HeartBeam (NASDAQCM:BEAT) has been revised to $3.57 / share. This is an increase of 10.53% from the prior estimate of $3.23 dated September 11, 2026. These figures represent aggregate analyst targets compiled as of September 29, 2026, and do not constitute an investment recommendation by Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $2.02 to a high of $5.25 / share. The average price target represents an increase of 752.03% from the latest reported closing price of $0.42 / share as of October 1, 2026.
The median target increased to $3.57 from $2.55, representing an absolute median change of $1.02. Looking at the target history, the mean target was $3.57 on October 2, 2026, after being $3.23 on September 15, 2026, and $3.44 on August 28, 2026. Over a longer horizon, the mean target has changed by -8.69% since its 90-day baseline of June 30, 2026. Within the observed twelve-month period, the mean target reached a high of $5.48 on May 14, 2026, and a low of $3.23 on September 15, 2026. For context, the stock's price performance shows a one-week change of +10.55% from a baseline close of $0.38 on September 24, 2026, and a one-month change of -7.85% from a baseline close of $0.45 on September 1, 2026.
In its latest earnings report on August 13, 2026, HeartBeam reported an actual EPS of -0.1 compared to an estimated -0.0918. Actual revenue was $0.00 against an estimate of $81,600.00, representing a revenue surprise of -100.00%. In terms of analyst sentiment, HC Wainwright & Co. downgraded the stock from Buy to Neutral on September 22, 2026. The recommendation trend as of September 1, 2026, shows a total of 9 recommendations, with 88.9% positive and 11.1% hold, compared to 10 total recommendations and 90.0% positive as of August 1, 2026.
HeartBeam operates in the Health Care Equipment sub-industry. Out of 23 covered companies in this sub-industry, 7 have seen target increases, 3 have been lowered, and 13 remain unchanged, with a median revision of 0.00% and a median implied change of +27.16%.
Among its peers, target revisions remained flat or slightly negative, while all three peers maintain positive implied changes based on their latest closing prices.
| Company name | Target revision | Implied change |
|---|---|---|
| iRhythm Holdings | 0.00% | +61.87% |
| HeartSciences | 0.00% | +162.21% |
| Boston Scientific | -0.41% | +53.62% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.